Amarin Corp Plc (AMRN)

[sts66]

Vivus still exists? I could have swore they went BK or merged with someone - like Belviq and Contrave, Qsymia was a total bomb, never got more than piddly sales because it was a combo of two ancient generics (phen and "dopamax"). I'm also surprised the FDA still allows it to be sold, because AFAIK VVUS never started the post marketing CVOT they were required to do - haven't checked for a while, but at least 5 yrs after Q was approved VVUS hadn't started it. ARNA's B was pulled over cancer concerns, something that came up in pre-clinical mice studies that was eventually glossed over after they refiled the NDA, got a CRL for that issue the first time. Glad you posted that link though - shows generics will go after brand name drugs "just because" even though they know they'll only be making a few shekels from selling it.

Per the what's more plausible question, of course the only answer is (b), but again it's hard to compare AMRN with VVUS - VVUS didn't get an sNDA approved that multiplied their addressable patient pops by a factor of 10 or 20. But I can see AMRN balking at giving H and R a one year early start, would allow Teva an earlier start too, and if they agreed to that you'd probably just invite more generics to the party.

Lastly, IIRC, when pre-trial discussions were held there was a very negative energy surrounding the talks, like "this is pointless" - I believe the final negotiation meeting they had only lasted a matter of hours - it was obvious nobody was budging off their position.